Michael A. Carson Takes on Role of President, CEO of Centene's Wellcare
Michael A. Carson has recently been appointed as president and CEO of Centene Corporation’s Medicare business, Wellcare.
Carson, who succeeds Richard Fisher, will now be responsible for Medicare business performance, strategy and the growth of Wellcare.
Carson
Before serving nearly three decades in the healthcare industry, Carson began his career in the United States Air Force, where he served for almost a decade.
He has since developed an array of leadership, operational and industry skills in both the payer and provider space with a focus on serving Medicare and dual-eligible populations.
Carson previously held the positions of CEO at CareAbout, a value-based primary and multi-specialty care startup, as well as at Bright Health Plan and Harvard Pilgrim Health Care.
Additionally, he led the rebuilding of Medicare ventures at Amerigroup and Anthem, while also serving leadership positions at ConcertoHealth and various Blue Cross Blue Shield plans.
In a press release, Carson shared his excitement to support Wellcare’s mission to transform the health of the communities it serves.
"I look forward to helping guide the Medicare business to realize its full potential, driving further innovation and growth as we collaborate with our Medicaid and Marketplace businesses and key provider and member services partners," Carson said.
Wellcare health plans provide government-sponsored healthcare programs nationwide, with some states exclusively offering Prescription Drug Plans (PDP), while the majority offer both PDP and Medicare Advantage (MA) Plans.
Centene has expanded its Medicare presence in recent years, offering various MA products across 37 states. To enhance consumer’s healthcare experience, Centene invests in service initiatives for both members and brokers, providing affordable options for its Medicare beneficiaries.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
